DURASERT E
Live / Applied — Fourth extension granted (statement of use) (as of 02 Dec 2025)
What this means for you
Not registered yet, but its 27 Mar 2023 filing date beats anything filed after it. If it registers, the owner can stop confusingly similar uses in the classes it covers.
Record
- Serial number
- 97858204
- Mark type
- Stylized text
- Filed
- 27 Mar 2023
- Published for opposition
- 31 Oct 2023
- Attorney of record
- Kimberly Jarman
Goods and services
- Class 005 — Pharmaceuticals: Injectable pharmaceutical preparations comprising erodible ingredients that facilitate the delivery of pharmaceuticals via injection into the posterior segment of the eye for the treatment of eye diseases and conditions of the retina, namely, wet age-related macular degeneration, non-proliferative diabetic retinopathy, diabetic macular edema and retinal vein occlusion and excluding dry eye, conjunctivitis, glaucoma and bacterial eye infections
Owner
- EYEPOINT US, INC., WATERTOWN, MA, US
- EyePoint Pharmaceuticals US, Inc., Watertown, MA, US
- EyePoint Pharmaceuticals US, Inc., Watertown, MA, US
Prosecution history
- 11 Mar 2026 — AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
- 02 Dec 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Dec 2025 — SOU EXTENSION 4 GRANTED
- 02 Dec 2025 — SOU EXTENSION 4 FILED
- 02 Dec 2025 — SOU TEAS EXTENSION RECEIVED
- 15 Sept 2025 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 09 Jun 2025 — SOU EXTENSION 3 GRANTED
- 09 Jun 2025 — SOU EXTENSION 3 FILED
- 09 Jun 2025 — SOU TEAS EXTENSION RECEIVED
- 02 Dec 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 02 Dec 2024 — SOU EXTENSION 2 GRANTED
- 02 Dec 2024 — SOU EXTENSION 2 FILED
- 02 Dec 2024 — SOU TEAS EXTENSION RECEIVED
- 13 Jun 2024 — NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
- 10 Jun 2024 — SOU EXTENSION 1 GRANTED